Memantine’s benefits in Alzheimer’s disease (AD) are modest and heterogeneous. We tested the feasibility of using sensitivity to acute memantine challenge to predict an individual’s clinical response. Eight participants completed a double-blind challenge study of memantine (placebo versus 20 mg) effects on autonomic, subjective, cognitive, and neurophysiological measures, followed by a 24-week unblinded active-dose therapeutic trial (10 mg bid). Study participation was well tolerated. Subgroups based on memantine sensitivity on specific laboratory measures differed in their clinical response to memantine, some by large effect sizes. It appears feasible to use biomarkers to predict clinical sensitivity to memantine.
PrinceM, WimoA, GuerchetM, AliG-C, WuY-T, PrinaM (2015) World Alzheimer Report 2015. The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. Alzheimer’s Disease International, London, pp. 10–29.
2.
AreosaSA, SherriffF, McShaneR (2005) Memantine for dementia. Cochrane Database Syst Rev (4), CD 003154.pub3.
3.
BakchineS, LoftH (2008) Memantine treatment in patients with mild to moderate Alzheimer’s disease: Results of a randomized, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 13, 97–107.
4.
PeskindER, PotkinSG, PomaraN, OttBR, GrahamSM, OlinJT, McDonaldS (2006) Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 14, 704–715.
5.
PomaraN, OttBR, PeskindE, ResnickEM (2007) Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: Secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis Assoc Disord. 21, 60–64.
6.
Bent-EnnakhilN, CosteF, XieL, AigbogunMS, WangY, KariburyoF, HartryA, BaserO, NeumannP, FillitH (2017) A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer’s disease patients. Neurol Ther. 6, 131–144.
7.
DoodyRS, TariotPN, PfeifferE, OlinJT, GrahamSM (2007) Meta-analysis of six-month memantine trials in Alzheimer’s disease. Alzheimers Dement. 3, 7–17.
8.
KavirajanH (2009) Memantine: A comprehensive review of safety and efficacy. Expert Opin Drug Saf. 8, 89–109.
9.
KishiT, MatsunagaS, IwataN (2017) The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: A meta-analysis. Neuropsychiatr Dis Treat. 13, 1909–1928.
10.
KishiT, MatsunagaS, OyaK, NomuraI, IkutaT, IwataN (2017) Memantine for Alzheimer’s disease: An updated systematic review and meta-analysis. J Alzheimers Dis. 60, 401–425.
11.
LightGA, SwerdlowNR (2015) Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. Ann N Y Acad Sci. 1344, 105–119.
12.
SwerdlowNR, BhaktaS, ChouHH, TalledoJA, BalvanedaB, LightGA (2016) Memantine effects on sensorimotor gating and mismatch negativity in patients with chronic psychosis. Neuropsychopharmacology. 41, 419–430.
MolinaJL, VoytekB, ThomasML, JoshiYB, BhaktaSG, TalledoJA, SwerdlowNR, LightGA (2020) Memantine effects on electroencephalographic measures of putative excitatory/inhibitory balance in schizophrenia. Biol Psychiatry Cogn Neurosci Neuroimaging. 5, 562–568.
15.
ThomasML, GreenMF, HellemannG, SugarCA, TarasenkoM, CalkinsME, GreenwoodTA, GurRE, GurRC, LazzeroniLC, NuechterleinKH, RadantAD, SeidmanLJ, ShilukAL, SieverLJ, SilvermanJM, SprockJ, StoneWS, SwerdlowNR, TsuangDW, TsuangMT, TuretskyBI, BraffDL, LightGA (2017) Modeling deficits from early auditory informationprocessing to psychosocial functioning in schizophrenia. JAMAPsychiatry. 74, 37–46.
16.
SwerdlowNR, van BergeijkDP, BergsmaF, WeberE, TalledoJ (2009) The effects of memantine on prepulse inhibition. Neuropsychopharmacology. 34, 1854–1864.
17.
KorostenskajaM, NikulinVV, KicicD, NikulinaAV, KähkönenS (2007) Effects of NMDA receptor antagonist memantine on mismatch negativity. Brain Res Bull. 72, 275–283.
18.
TikhonravovD, NeuvonenT, PertovaaraA, SaviojaS, RuusuvirtaT, NäätänenR, CarlsonS (2010) Dose-related effects of memantine on a mismatch negativity-like response in anesthetized rats. Neuroscience. 167, 1175–1182.
19.
MaJ, MuftiA, StanLeung L (2015) Effects of memantine on hippocampal long-term potentiation, gamma activity, and sensorimotor gating in freely moving rats. Neurobiol Aging. 36, 2544–2554.
20.
PovyshevaNV, JohnsonJW (2016) Effects of memantine on the excitation-inhibition balance in prefrontal cortex. Neurobiol Dis. 96, 75–83.
21.
HughesAJ, LeesAJ, SternGM (1990) Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet. 336, 32–34.
22.
BillerBM (2007) Concepts in the diagnosis of adult growth hormone deficiency. Horm Res. 68(Suppl 5), 59–65.
23.
FruchterO, YiglaM (2009) Bronchodilator response after negative methacholine challenge test predicts future diagnosis of asthma. J Asthma. 46, 722–725.
24.
GredenJF, KronfolZ, GardnerR, FeinbergM, MukhopadhyayS, AlbalaAA, CarrollBJ (1981) Dexamethasone suppression test and selection of antidepressant medications. J Affect Disord. 3, 389–396.
25.
FrodlT (2017) Recent advances in predicting responses to antidepressant treatment. F1000Res. 6, F1000 Faculty Rev-619.
26.
LescaG, RudolfG, BruneauN, LozovayaN, LabalmeA, Boutry-KryzaN, SalmiM, TsintsadzeT, AddisL, MotteJ, WrightS, TsintsadzeV, MichelA, DoummarD, LascellesK, StrugL, WatersP, de BellescizeJ, VrielynckP, de Saint MartinA, VilleD, RyvlinP, ArzimanoglouA, HirschE, VincentA, PalD, BurnashevN, SanlavilleD, SzeptowskiP (2013) GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet. 45, 1061–1066.
27.
LiD, YuanH, Ortiz-GonzalezXR, MarshED, TianL, McCormickEM, KosobuckiGJ, ChenW, SchulienA, ChiavacciR, TankovicA, NaaseC, BruecknerF, von Stülpnagel-SteinbeisC, HuC, KusumotoH, HedrickUBS, ElsenG, HörtnagelK, AizenmanE, LemkeJR, HakonarsonH, TraynelisSF, FalkMJ (2016) GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers. Am J Hum Genet. 99, 802–816.
28.
PiersonTM, YuanH, MarshED, Fuentes-FajardoK, AdamsDR, MarkelloT, GolasG, SimeonovDR, HollomanC, TankovicA, KaramchandaniMM, SchreiberJM, MullikinJC, PhD for the NISC Comparative Sequencing Program; TifftCJ, ToroC, BoerkoelCF, TraynelisSF, GahlWA (2014) GRIN2A mutation and early-onset epileptic encephalopathy: Personalized therapy with memantine. Ann Clin Transl Neurol. 1, 190–198.
29.
DuffK, Humphreys ClarkJD, O’BryantSE, MoldJW, SchifferRB, SutkerPB (2008) Utility of the RBANS in detecting cognitive impairment associated with Alzheimer’s disease: Sensitivity, specificity, and positive and negative predictive powers. Arch Clin Neuropsychol. 23, 603–612.
HejlA-M, GlenthøjB, MackeprangT, HemmingsenR, WaldemarG (2004) Prepulse inhibition in patients with Alzheimer’s disease. Neurobiol Aging. 25, 1045–1050.
32.
PerriolMP, DujardinK, DerambureP, MarcqA, BourriezJ-L, LaureauE, PasquierF, DefebvreL, DesteeA (2005) Disturbance of sensory filtering in dementia with Lewy bodies: Comparison with Parkinson’s disease dementia and Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 76, 106–108.
33.
OsipovaD, PekkonenE, AhveninenJ (2006) Enhanced magnetic auditorysteady-state response in early Alzheimer’s disease. ClinNeurophysiol. 117, 1990–1995.
34.
UekiA, GotoK, SatoN, HiroyukiI, MoritaY (2006) Prepulse inhibition of acoustic startle response in mild cognitive impairment and mild dementia of Alzheimer type. Psychiatry Clin Neurosci. 60, 55–62.
35.
van DeursenJA, VuurmanEFPM, van Kranen-MastenbroekVHJM, VerheyFRJ, RiedelWJ (2011) 40-Hz steady state response in Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging. 32, 24–30.
36.
LindínM, CorreaK, ZurróM, DiazF (2013) Mismatch negativity (MMN) amplitude as a biomarker of sensory memory deficit in amnestic mild cognitive impairment. Front Aging Neurosci. 5, 79.
37.
BaldewegT, HirschSR (2015) Mismatch negativity indexes illness-specific impairments of cortical plasticity in schizophrenia: A comparison with bipolar disorder and Alzheimer’s disease. Int J Psychophysiol. 95, 145–155.
38.
HedgesD, JanisR, MickelsonS, KeithC, BennettD, BrownBL (2016) P300 amplitude in Alzheimer’s disease: A meta-analysis and meta-regression. Clin EEG Neurosci. 47, 48–55.
39.
DanjouP, ViardotG, MauriceD, GarcésP, WamsEJ, PhillipsKG, Bertaina-AngladeV, McCarthyAP, PembertonDJ (2019) Electrophysiological assessment methodology of sensory processingdysfunction in schizophrenia and dementia of the Alzheimer type. Neurosci Biobehav Rev. 97, 70–84.
40.
EllwangerJ, GeyerMA, BraffDL (2003) The relationship of age to prepulse inhibition and habituation of the acoustic startle response. Biol Psychol. 62, 175–195.
41.
BhaktaSG, ChouHH, RanaB, TalledoJA, BalvanedaB, GaddisL, LightGA, SwerdlowNR (2016) Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy. Psychopharmacology (Berl). 233, 2399–2410.
42.
ZhengW, LiXH, YangXH, CaiDB, UngvariGS, NgCH, WangSB, WangYY, NingYP, XiangYT (2018) Adjunctive memantine for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Psychol Med. 48, 72–81.
43.
SwerdlowNR, BhaktaSG, TalledoJ, KotzJ, RobertsBZ, CliffordRE, ThomasML, JoshiYB, MolinaJL, LightGA (2020) Memantine effects on auditory discrimination and training in schizophrenia patients. Neuropsychopharmacology. 45, 2180–2188.
44.
ToccoM, GrahamSM (2010) Effects of memantine treatment on language abilities and functional communication in patients with moderate to severe Alzheimer’s disease: A review of data. Eur J Neurol. 17, 357–357.
45.
SaxtonJ, HofbauerRK, WoodwardM, GilchristNL, PotocnikF, HsuHA, MillerML, PejovićV, GrahamSM, PerhachJL (2012) Memantine andfunctional communication in Alzheimer’s disease: Results of a12-week, international, randomized clinical trial. J AlzheimersDis. 28, 109–118.
46.
SchulzJB, RainerM, KlünemannH-H, KurzA, WolfS, SternbergK, TennigkeitF (2011) Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer’s disease: Results of a 16-week open-label trial. J Alzheimers Dis. 25, 463–475.
47.
FerrisS, IhlR, RobertP, WinbladB, GatzG, TennigkeitF, GautheirS (2009) Treatment effects of Memantine on language in moderate to severe Alzheimer’s disease patients. Alzheimers Dement. 5, 369–374.
48.
GrahamSM, PerhachJL (2012) Memantine and functional communicationin Alzheimer’s disease: Results of a 12-week, international,randomized clinical trial. J Alzheimers Dis. 28, 109–118.
49.
DeguilJ, RavasiL, LambertyY, AuffretA, PayouxP, LeroyC, DerambureP, BordetR (2016) Early development of symptomatic drugs in AD: A systematic review of the use of biomarkers. CNS Neurol Disord Drug Targets. 15, 823–836.
